Results 21 to 30 of about 5,401 (225)

Identification of novel compounds against Trypanosoma cruzi using AlphaFold structures [PDF]

Computational and Structural Biotechnology Journal
Chagas disease is a neglected tropical zoonosis caused by the protozoan Trypanosoma cruzi. The two approved medications for treating this disease show variable efficacy in the chronic phase, highlighting the need for new therapeutic interventions.
Albert Ros-Lucas, Alejandra Saeteros, Juan Carlos Gabaldón-Figueira, Nieves Martínez-Peinado, Elisa Escabia, Joaquim Gascón, Julio Alonso-Padilla   +6 more
doaj   +2 more sources

Effect of pimecrolimus on postoperative peritoneal adhesions in rat: An experimental study [PDF]

International Journal of Surgery Open, 2020
Introduction Postoperative peritoneal adhesions (PPAs) is a common complication of abdominal surgeries causing significant morbidity and mortality. The inflammatory response to damaged peritoneal tissue is a speculated culprit.
H. Azadi, Abdoulhossein Davoodabadi, H. Akbari, Hmid Reza Benafsheh, Mahdi Norroddini, Abbas Hajian   +5 more
semanticscholar   +2 more sources

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023 [PDF]

Diseases
Vitiligo, an autoimmune disorder causing depigmented skin patches, includes two types, segmental (SV) and non-segmental (NSV). Previously, NSV was off-label treated using Calcineurine inhibitors (Tacrolimus and Pimecrolimus).
Saleh F. Alqifari, Musaab Habibulla Gari, Jeff J. Guo, Shoroq Alamin, Aya K. Esmail, Abdullah K. Esmail, Heba R. Hamad, Ahmed Aljabri, Amirah M. Alatawi, Laila A. Albishi, Mohammed Olaythah Alraddadi, Helal F. Hetta   +11 more
doaj   +2 more sources

Pimecrolimus Is a Potent Inhibitor of Allergic Reactions to Hymenopteran Venom Extracts and Birch Pollen Allergen In Vitro. [PDF]

PLoS ONE, 2015
Pimecrolimus (Elidel, SDZ ASM 981) is an anti-inflammatory and immunomodulatory 33-epichloro-derivative of macrolactam ascomycin, with low potential for affecting systemic immune responses compared with other calcineurin inhibitors, cyclosporin A and ...
Petr Heneberg, Kamila Riegerová, Petr Kučera   +2 more
doaj   +1 more source

Pimecrolimus protects neuron‐like SH‐SY5Y cells against anti‐inflammatory and anti‐oxidant effects of both microglial secretome and hydrogen peroxide

Scandinavian Journal of Immunology, 2023
Calcineurin inhibitors have been found to exhibit a preventive role against neuroinflammation, which represents a crucial underlying mechanism in neurodegenerative diseases (ND).
F. Koçancı, Azize Yasemin Goksu Erol, Fatma Yıldız, Hamiyet Eci̇roglu   +3 more
semanticscholar   +1 more source

Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas

EJD. European journal of dermatology, 2023
This systematic literature review (SLR) and meta-analysis assessed the efficacy and safety of pimecrolimus vs other topical treatments in patients with mild-to-moderate atopic dermatitis (AD), focusing on children and sensitive skin areas.
T. Luger, Chia-Yu Chu, A. Elgendy, Sabeera Begum Binti Kader Ibrahim, Nikolay Murashkin, Sandip Ranjan, Zuotao Zhao   +6 more
semanticscholar   +1 more source

Low-dose Pimecrolimus, an FDA-approved Calcineurin Inhibitor, Sensitizes Drug-resistant Cancer Cells via Strong P-gp Inhibition

Anticancer Research, 2023
Background/Aim: Co-treatment with calcineurin inhibitors, such as tacrolimus and cyclosporin A, can sensitize chemotherapy-resistant cancer cells with P-glycoprotein (P-gp)-over-expression.
Jae Hyeon Park, Ji-Sun Lee, JOO-KYUNG Shin, Swati Sharma, Hyung Sik Kim, Sungpil Yoon   +5 more
semanticscholar   +1 more source

Safety and efficacy of pimecrolimus versus vehicle for the treatment of atopic dermatitis in adults and paediatric population: a systematic review and meta-analysis

Annals of Medicine and Surgery, 2023
Introduction: Atopic dermatitis remains a widespread problem affecting various populations globally. While numerous treatment options have been employed, pimecrolimus remains a potent and viable option.
S. E. Akhtar, S. Shakil, S. Farooqui, Tarek Khedro, Ahmad Alzufairi, M. A. Niaz, Saifullah Syed, R.A.M. Jiffry, Abdulla K. Alsubai, Abdulla Almesri, Hebatalla Ismail, K. Khan, A. Al-Hindawi, H. K. Ali, Timothy O. Falodun, Aysa Tabassi, Aylin Tabassi, Talal Almas   +17 more
semanticscholar   +1 more source

The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials

Cureus, 2022
Facial seborrheic dermatitis (SD) is a chronic inflammatory skin condition that can affect the quality of life with frequent recurrences. There is no medication as yet to cure this disease completely.
Odeh Alsmeirat, S. Lakhani, Musab Egaimi, O. Idris, Mohamed Elkhalifa   +4 more
semanticscholar   +1 more source

Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach

Dermatologic Therapy, 2022
Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease with rising prevalence. Topical corticosteroids (TCS) are recommended as first-line therapy for patients with AD in China; however, corticophobia is a widespread concern, which can ...
Zuotao Zhao, Xing-Hua Gao, Wei Li, Hua Wang, Yunsheng Liang, Jian-xiao Tang, Xu Yao, Huan Zhao, T. Luger   +8 more
semanticscholar   +1 more source